FLT3 and acute myeloid leukemia: Although Flt3 activating mutations have been widely associated with the poorer prognosis of AML patients, the fact that more than 70% of AMLs express wild-type Flt3 [24], [33], [34], implies that the native receptor is also important in the enhancement of survival and proliferation of leukemic blasts.